We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Radcal IBA  Group

Download Mobile App




New Way to Treat Chronic Pain Shows Promise

By HospiMedica staff writers
Posted on 18 May 2004
In a series of animal studies, scientists have demonstrated the therapeutic potential of selectively deleting specific nerve cells from the nervous system that convey severe chronic pain. More...
Their findings were published in the May 1, 2004, issue of the Journal of Clinical Investigation.

The treatment was used on eight dogs severely affected by osteroarthritis, cancer, or both. All eventually became more active and later walked with slight or no limps. None showed any adverse side effects from the treatment and their need for other pain-controlling medications was eliminated or greatly reduced. The researchers also selectively deleted the nerve cells called C-fiber neurons from various human neurons cultured together in the laboratory, an indication that the strategy might work in people. C-fibers convey sensations of noxious heat and certain inflammatory signals to the central nervous system.

The treatment is based on using an old drug called resiniferatoxin (RTX) a new way. RTX attaches to a protein called vanilloid receptor 1(VR1), displayed on the surface of certain types of heat-pain-sensing neurons, and prompts a brief influx of calcium through a channel but only in those cells that manufacture the ion channel. This RTX-induced flow of calcium can overdose, seriously disable, and ultimately kill these neurons. By applying RTX directly to the dorsal root ganglia, the scientists knew they could selectively delete specific neurons, such as C-fibers, that exhibit large amounts of VR1 protein. This led to the idea of permanently turning off their chronic pain signals.

"We realized that by focusing on RTX's ability to kill cells, we could apply it therapeutically,” said lead author Dr. Laszlo Karai, a scientist at the U.S. National Institute of Dental and Craniofacial Research (NIDCR, Bethesda, MD, USA). "The technique selectively deletes certain neurons but leaves other untouched.”





Related Links:
National Institute of Dental and Craniofacial Research

Platinum Member
STI Test
Vivalytic Sexually Transmitted Infection (STI) Array
Gold Member
Enteral Feeding Pump
SENTINELplus
OR Table Accessory
Angular Accessory Rail
Morcellator
TCM 3000 BL
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Surgical Techniques

view channel
Image: Professor Bumsoo Han and postdoctoral researcher Sae Rome Choi of Illinois co-authored a study on using DNA origami to enhance imaging of dense pancreatic tissue (Photo courtesy of Fred Zwicky/University of Illinois Urbana-Champaign)

DNA Origami Improves Imaging of Dense Pancreatic Tissue for Cancer Detection and Treatment

One of the challenges of fighting pancreatic cancer is finding ways to penetrate the organ’s dense tissue to define the margins between malignant and normal tissue. Now, a new study uses DNA origami structures... Read more

Patient Care

view channel
Image: The portable biosensor platform uses printed electrochemical sensors for the rapid, selective detection of Staphylococcus aureus (Photo courtesy of AIMPLAS)

Portable Biosensor Platform to Reduce Hospital-Acquired Infections

Approximately 4 million patients in the European Union acquire healthcare-associated infections (HAIs) or nosocomial infections each year, with around 37,000 deaths directly resulting from these infections,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.